Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DuoGenic StemCellsROCO:7607 +1.47%30 Debt-to-Equity is 0.64 as of Jun. 2026, which is 327% above its 10-year median of 0.15. GuruFocus rates ROCO:7607 with a GF Score™ of 30/100 and a GF Value™ of NT$28.17 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 966 Biotechnology companies, DuoGenic StemCells ranks worse than 80.43% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for DuoGenic StemCells's Debt-to-Equity or its related term are showing as below:
ROCO:7607'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.15 Max: 2.13
Current: 0.64
During the past 5 years, the highest Debt-to-Equity Ratio of DuoGenic StemCells was 2.13. The lowest was 0.02. And the median was 0.15.
ROCO:7607's Debt-to-Equity is ranked worse than 80.43% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs ROCO:7607: 0.64
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
DuoGenic StemCells Debt-to-Equity Related Terms
DuoGenic StemCells Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, DuoGenic StemCells's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a Debt-to-Equity of 0.64 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DuoGenic StemCells and its competitors. This is 327% above median its historical median of 0.15. Over the past decade, DuoGenic StemCells' Debt-to-Equity has ranged from 0.02 to 2.13. According to the industry distribution chart, DuoGenic StemCells ranks #777 out of 966 companies in the Biotechnology industry, placing it in the top 80.4%.
Is DuoGenic StemCells' Debt-to-Equity too high?
DuoGenic StemCells' current Debt-to-Equity of 0.64 is 327% above median its 10-year median of 0.15. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 2.13. The Biotechnology industry median Debt-to-Equity is 0.15. DuoGenic StemCells' value of 0.64 is 326.7% above this industry median. Based on the distribution chart, DuoGenic StemCells ranks #777 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DuoGenic StemCells has a GF Score™ of 30/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #777 out of 966 companies for Debt-to-Equity. This places DuoGenic StemCells in the lower half of its industry. The industry median Debt-to-Equity is 0.15. DuoGenic StemCells' value of 0.64 is 326.7% above this benchmark. Historically, DuoGenic StemCells' own Debt-to-Equity has ranged from 0.02 to 2.13 over the past decade. While the company's 10-year median is 0.15 vs. the industry median of 0.15, DuoGenic StemCells has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DuoGenic StemCells's current Debt-to-Equity of 0.64 is 326.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on DuoGenic StemCells and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DuoGenic StemCells's current Debt-to-Equity is 0.64, which is 327% above median its own 10-year median of 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$28.17, compared to a current price of NT$10.35 — trading 63.3% below its estimated fair value. The current Debt-to-Equity is 0.64, which is 327% above median its 10-year median of 0.15 and 326.7% above the Biotechnology industry median of 0.15. DuoGenic StemCells' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current Debt-to-Equity is 0.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$10.35 is trading 63.3% below its estimated GF Value™ of NT$28.17.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
Debt-to-Equity: 0.64 (327% above median its 10-year median of 0.15)
GF Value™: NT$28.17 vs. price of NT$10.35 (63.3% below fair value)
Industry Position: 326.7% above the Biotechnology median (#777 of 966)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
30GF Score
Get the complete analysis for ROCO:7607
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
